Dr. Sharman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
520 Country Club Pkwy
Eugene, OR 97401Phone+1 541-683-5001Fax+1 541-683-1422
Education & Training
Stanford Health Care-Sponsored Stanford UniversityFellowship, Medical Oncology, 2005 - 2008
Massachusetts General HospitalResidency, Internal Medicine, 2001 - 2004
University of California, Davis, School of MedicineClass of 2001
Certifications & Licensure
CA State Medical License 2004 - Present
OR State Medical License 2008 - 2025
MA State Medical License 2003 - 2006- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Clinical Trials
- A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma Start of enrollment: 2011 Aug 01
- Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies Start of enrollment: 2013 Mar 14
- MEK162 for Patients With RAS/RAF/MEK Activated Tumors Start of enrollment: 2013 Oct 10
- Join now to see all
Publications & Presentations
PubMed
- OUTREACH: Phase 2 study of lisocabtagene maraleucel as outpatient or inpatient treatment at community sites for R/R LBCL.Yuliya Linhares, Cesar O Freytes, Mohamad Cherry, Carlos Bachier, Michael B Maris
Blood Advances. 2024-09-30 - 1714 citationsTargeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic LeukemiaJohn C. Byrd, Richard R. Furman, Steven Coutre, Ian W. Flinn, Jan A. Burger
The New England Journal of Medicine. 2013-07-03 - 254 citationsObjective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotinSteven M. Horwitz, Ranjana H. Advani, Nancy L. Bartlett, Eric D. Jacobsen, Jeff P. Sharman
Blood. 2014-05-15
Journal Articles
- An Open‐Label Phase 2 Trial of Entospletinib in Indolent Non‐Hodgkin Lymphoma and Mantle Cell LymphomaJeff P Sharman, David J Andorsky, Christopher A Yasenchak, Kathryn S Kolibaba, British Journal of Haematology
- IdelalisibFurhman, New England journal
Abstracts/Posters
- Improvements in Health-Related Quality of Life and Symptoms in Patients with Previously Untreated Chronic Lymphocytic Leukemia: Final Results from the Phase II GIBB St...Jeff P. Sharman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Updated Analys...Jeff P. Sharman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Evolution in Practice Patterns and Differences Among Experts and Community Healthcare Providers in the Treatment of Patients with Chronic Lymphocytic LeukemiaJeff P. Sharman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- Final Results from the Multicenter, Open-Label, Phase II GIBB Study of Obinutuzumab+Bendamustine in Previously Untreated Patients with Chronic Lymphocytic Leukemia61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Indolent Lymphomas: The Marathon Has a New Course61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Debulking Eliminates Need for Hospitalization Prior to Initiating Frontline Venetoclax Therapy in Previously Untreated CLL Patients: A Phase 3b Study61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Join now to see all
Press Mentions
Establishing Goals of Treatment in Relapsed/Refractory Mantle Cell LymphomaOctober 1st, 2024- CALQUENCE plus Obinutuzumab Demonstrated Sustained Survival Benefit in 1st-Line Chronic Lymphocytic Leukemia with 90% of Patients Surviving Five Years in ELEVATE-TN TrialJune 4th, 2022
- Triplet Regimen Steps up as Potential First-Line CLL TherapyNovember 18th, 2021
- Join now to see all
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
